The Diversification Bet
Eli Lilly has committed more than $20 billion to ten acquisitions in six months, not one of them a tablet. Ibumix reads the pattern against its own predictions on AI, demographics and delivery.
Read moreCategory: Technology
The First Battle, Won
The First Battle, Won How SNAC turned semaglutide into a tablet — and why 99% of the dose still never arrives In […]
Read moreThe Three Battles Every Oral Peptide Must Win
Semaglutide survives a week in the bloodstream as an injection. As a tablet, it must first survive stomach acid, cross the intestinal wall, and stay active in the blood — three separate battles most peptides never win.
Read moreWhy GLP-1 Disappears in Minutes — and Ozempic Doesn’t
Natural GLP-1 lasts about a minute in the body. Semaglutide, built from it, lasts a week. The biology behind Ozempic, Wegovy and Mounjaro.
Read moreWho Decided How Big a Tablet Should Be?
The hidden engineering behind every pill you’ve ever taken The size of a tablet feels like a design decision. It isn’t. It […]
Read moreThe Most Valuable Data in Pharma Is the Data Nobody Keeps
Negative results are the missing fuel for AI drug discovery. The companies that win will be the ones with the highest failure-capture […]
Read moreThe Ordered Liquid: potassium cinnamate, GCC and the liquid crystal beneath Cinnamix
A liquid crystal is a paradox — a fluid that flows like a liquid yet holds internal order like a crystal. Cinnamix […]
Read moreNaproxen: A Case Study in Conservative Formulation
When a superior molecule is held back by its delivery system Naproxen’s long-lasting effect is well known. Its slow start is the […]
Read moreThe End of the Tablet Era
The best-selling drug in the world is no longer a tablet. The pipeline behind it is no longer led by small molecules. […]
Read moreA polysorbate cannot do this alone
Why both small-molecule solubility and biologic stability hit ceilings the surfactant cannot raise — and what an engineered architecture changes. Polysorbates 20 […]
Read more